Log in

PHRX Pharmadrug, Inc. CSE · Canada

Pharmadrug (PHRX) news

Pharmadrug, Inc. is a public biotech or pharmaceutical company listed on CSE under the ticker PHRX, recorded under Canada. The directory classifies it as Biopharma / pharmaceutical profile checked. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Pharmadrug news

We have not published a story on Pharmadrug yet. When there is news, it will appear here.

Questions about Pharmadrug

What is the ticker symbol of Pharmadrug?

Pharmadrug, Inc. trades under the ticker PHRX on CSE.

Where is Pharmadrug listed?

Pharmadrug, Inc. is listed on CSE. Our directory also records these other listings: GETTEX:G11; NEO:PHRX; OTC:LMLLF.

Which country or territory is Pharmadrug listed under?

Our directory records Pharmadrug, Inc. under Canada.

What does Pharmadrug do?

Our directory classifies Pharmadrug, Inc. as: Biopharma / pharmaceutical profile checked. This is a directory classification, not a description of the pipeline.

What is the ISIN of Pharmadrug?

The ISIN recorded for Pharmadrug, Inc. is CA71716W2040.

Does aibio.space cover Pharmadrug?

aibio.space lists Pharmadrug, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Pharmadrug?

Companies in our directory listed in the same country and business area as Pharmadrug: Restart Life Sciences, Cipher Pharmaceuticals, Noveris Health Sciences, Neural Therapeutics, CanaQuest Medical, Bausch Health Companies.

Investor discussion: Pharmadrug

Members talk about Pharmadrug (PHRX). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open CSE:PHRX on TradingView.

Listing details

Pharmadrug, Inc. is a public biotech or pharmaceutical company listed on CSE under the ticker PHRX, recorded under Canada. The directory classifies it as Biopharma / pharmaceutical profile checked. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Pharmadrug, Inc.
Ticker
PHRX
Listing
CSE
Country or territory
Canada
Business scope
Biopharma / pharmaceutical profile checked
ISIN
CA71716W2040
Other listed symbols
GETTEX:G11; NEO:PHRX; OTC:LMLLF
Last quote in directory
2026-10-21
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.